Abstract library

10 results for "CD117".
#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry
Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Dieter Hörsch
#995 Neuroendocrine Tumor of the Appendix in Pregnancy
Introduction: Despite the fact the appendix is one of the rarest anatomical locations of neuroendocrine tumors (NETs) in the digestive system, the appendicular neuroendocrine tumor (A-NET) remains one of the most common tumors of the appendix.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Andrejs Vanags
Authors: Vanags A, Simtniece Z, Strumfa I, ...
#1082 Characterization and Prognosis of Patients with Metastatic Lung Carcinoid Tumors
Introduction: Data on metastatic lung carcinoid tumors are limited.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD, PhD Thomas Walter
#1235 The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion.
Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: Registry, Belgium
#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients
Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Ron Basuroy
#1375 Merkel Cell Carcinoma of the Knee Treated with Somatostatin Analogue and Radiotherapy: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ivana Puliafito
#1411 Role of Preoperative Computed Tomography (CT) in Diagnostics and Disease Stage of Small Bowel NEN: Correlation with Pathology Based on pTNM WHO 2010 Classification
Introduction: SbNEN are difficult to diagnose on standard CT without bowel preparation. Knowledge about specific radiological signs is essential.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jakub Pałucki
#1780 PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)
Introduction: Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, interacting with two ligands, PD-L1 and PD-L2. The former is expressed in many human cancers and is used as a selection criterion for indication of checkpoint inhibitor therapies. PD-L1 is also a potential target for checkpoint inhibitors in pNET therapy, however no data on prevalence of PD-L1 expression and potential associations to clinico-pathologic features is available.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MMed Charalampos Saganas
#1822 Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 gastric Neuroendocrine Neoplasms (gNENs) are defined when atrophic body gastritis is associated. They are mostly multiple, small, with a low grade histology with low metastatic risk. Data on factors associated with malignant tumor behavior in these patients are scarce.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Maria Rinzivillo
Keywords: Gastric NEN, Grading
#2020 Expression of Somatostatin Receptors in Neuroendocrine Tumors of the Lungs with Various Degrees of Malignancy
Introduction: Diagnostics and management of patients with neuroendocrine tumors of the lung requires an individual approach
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Larisa Gurevich
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.